ArticleBritish journal of cancer2012
MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Diagnostic performance of microRNAs in testicular germ cell tumors: a systematic review and meta-analysis.Aging · 2021Pooled it
- The Diagnostic Accuracy of miR-371a-3p for Testicular Germ Cell Tumors: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2021Pooled it
- Solid tumors of childhood display specific serum microRNA profiles.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Trial
- External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.The Canadian journal of urology · 2026Article
- Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignature.Nature communications · 2026Article
- Differences of sex development.Nature reviews. Disease primers · 2025Review
- Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.International urology and nephrology · 2025Review
- Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors.PloS one · 2025Article
- The New Tumour Biomarker miRNA-371-3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines.Journal of cellular and molecular medicine · 2024Article
- The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives.Medicina (Kaunas, Lithuania) · 2023Review
- Review
- MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors.Journal of cancer research and clinical oncology · 2023Article
- Biomarkers of disease recurrence in stage I testicular germ cell tumours.Nature reviews. Urology · 2022Review
- Emerging Role of Biomarkers in Testicular Germ Cell Tumors.Current oncology reports · 2022Review
- Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.Frontiers in oncology · 2022Article
- The values of systemic immune-inflammation index and neutrophil-lymphocyte ratio in predicting testicular germ cell tumors: A retrospective clinical study.Frontiers in oncology · 2022Article
- DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.Frontiers in oncology · 2022Article
- The utility of cfDNA in TGCT patient management: a systematic review.Therapeutic advances in medical oncology · 2022Review
- Abnormal Circulating Maternal miRNA Expression Is Associated with a Low (<4%) Cell-Free DNA Fetal Fraction.Diagnostics (Basel, Switzerland) · 2021Article
- The Role ofInternational journal of molecular sciences · 2021Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundmiRNAs are small noncoding RNA molecules that can be released into body fluids. Germ cell tumours (GCTs) overexpress miRNAs of the miR-371-3 cluster. Thus, serum levels of these miRNAs may correlate with tumour load.
methodsmiRNAs of the miR-371-3 cluster were quantified in cubital vein blood samples of 20 GCT patients with clinical stage 1, and of 4 patients with advanced stages before and after treatment. In six patients testicular vein blood (TVB) was examined additionally. Seventeen healthy males served as controls. Likewise, expression of miRNAs in 15 matching tumour specimens was measured.
resultsIn all patients, serum levels of miRNAs 371-3 were much higher than in controls. In stage 1, levels decreased postoperatively 336.7-fold, 7.4-fold, and 7.7-fold for miRNAs 371a-3p, 372, and 373-3p, respectively (P<0.01). Also, in those cases with advanced disease levels dropped to the normal range after completion of treatment. miR-371-3 levels in TVB exceeded those in peripheral blood in all cases. Expression of miR-371a-3p was also documented in tumour tissue. However, no correlation was found regarding the extent of miRNA expression in tissue and the values measured in matching serum.
conclusionThus, miR-371a-3p serum level appears to be a useful biomarker in GCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.